Clinical trial
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN® -RSV Vaccine in Adults ≥60 Years of Age
NCT05238025 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN® -RSV Vaccine in Adults ≥60 Years of Age
- Lead sponsor
- Bavarian Nordic
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- April 19, 2022
- Completion date
- September 1, 2023
- Enrollment
- 20,419 (actual)
- Sites
- 120
Conditions
As the registry lists them; a condition with its own page is linked.